Want to see ANVS full AI Analyst Report?
ANVS Stock Chart & Stats
$1.87
-$0.04(-0.79%)
At close: 4:00 PM EST
$1.87
-$0.04(-0.79%)
Day’s Range― - ―
52-Week Range$1.54 - $5.50
Previous CloseN/A
Volume368.97K
Average Volume (3M)982.83K
Market Cap
$74.02M
Enterprise Value$47.88
Total Cash (Recent Filing)$14.22M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.23
Next Earnings
Aug 18, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.72
Shares Outstanding42,541,866
10 Day Avg. Volume959,502
30 Day Avg. Volume982,829
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.00Price Target Upside327.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.86
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal Phase 3 EnrollmentCompleting enrollment in a large, biomarker-confirmed Phase 3 trial materially de-risks the development timeline. It enables planned six-month and 18-month readouts, strengthens regulatory and clinical credibility, and creates clearer paths for partnering or milestone-driven financing over the next 2–3 years.
Debt-Free Balance SheetHaving no reported debt lowers solvency and interest burden risk, preserving strategic optionality while the company advances late-stage trials. Debt-free status supports flexibility in choosing financing routes or structuring partnerships and reduces fixed-cost pressure on a pre-revenue biotech over the medium term.
Strengthened Governance & Compensation FlexibilityShareholder approval to expand equity incentive capacity and biennial say-on-pay improves the company’s ability to retain and motivate clinical and executive talent critical for complex trials. Stronger governance and auditor ratification also support investor confidence and long-term organizational stability.
Bears Say
Zero Revenue And Persistent LossesNo product revenue means the company’s fundamental value hinges entirely on clinical success. Persistent operating losses increase execution and financing risk, make long-term planning dependent on trial outcomes, and leave the balance sheet exposed until regulatory approvals or partner/license revenues materialize.
Consistent Negative Cash FlowSustained negative operating and free cash flow reduces runway and forces recurrent capital raises. Volatile free cash flow complicates forecasting and resource allocation for trials, increasing the likelihood of dilutive financings and constraining the company’s ability to invest in parallel development or commercialization readiness.
Reliance On Dilutive Equity FinancingRepeated stock and warrant offerings to fund trials highlight dependence on capital markets and risk of shareholder dilution. This financing pattern can compress per-share economics long-term, signal limited access to non-dilutive funding, and create ongoing issuance risk until product revenues or substantial partnerships emerge.
Annovis Bio News
ANVS FAQ
What was Annovis Bio Inc’s price range in the past 12 months?
Annovis Bio Inc lowest stock price was $1.54 and its highest was $5.50 in the past 12 months.
What is Annovis Bio Inc’s market cap?
Annovis Bio Inc’s market cap is $74.02M.
When is Annovis Bio Inc’s upcoming earnings report date?
Annovis Bio Inc’s upcoming earnings report date is Aug 18, 2026 which is in 30 days.
How were Annovis Bio Inc’s earnings last quarter?
Annovis Bio Inc released its earnings results on May 15, 2026. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.395 by -$0.235.
Is Annovis Bio Inc overvalued?
According to Wall Street analysts Annovis Bio Inc’s price is currently Undervalued.
Does Annovis Bio Inc pay dividends?
Annovis Bio Inc does not currently pay dividends.
What is Annovis Bio Inc’s EPS estimate?
Annovis Bio Inc’s EPS estimate is -0.45.
How many shares outstanding does Annovis Bio Inc have?
Annovis Bio Inc has 42,541,866 shares outstanding.
What happened to Annovis Bio Inc’s price movement after its last earnings report?
Annovis Bio Inc reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.395. Following the earnings report the stock price went down -3.286%.
Which hedge fund is a major shareholder of Annovis Bio Inc?
Currently, no hedge funds are holding shares in ANVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annovis Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (327.81% Upside)
$8.00 (327.81% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 70%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth $142.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.9%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.07%
12-Months-Change
Fundamentals
Return on Equity
-318.08%
Trailing 12-Months
Asset Growth
-39.25%
Trailing 12-Months
Company Description
Annovis Bio Inc
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
ANVS Stock 12 Month Forecast
Average Price Target
$8.00
▲(327.81% Upside)
Technical Analysis
Whitehawk Therapeutics
―
Precision BioSciences
―
Greenwich LifeSciences
―
Acumen Pharmaceuticals
―
Coya Therapeutics, Inc.
―
Ownership Overview
11.32% Insiders
2.59% Mutual Funds
0.05% Other Institutional Investors
82.00% Public Companies and
Individual Investors